Phase 1 Obesity Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older at the time of signing the consent form
- People with a body mass index (a measure of body weight relative to height) between 25.0 and 45.0, where the extra weight is due to excess body fat, as assessed by the study doctor
- People with type 2 diabetes who were diagnosed more than 180 days before the screening visit, and who are either taking no diabetes medications, or taking a stable dose of metformin (at the highest tolerated daily dose for at least 90 days before screening)
Who may not be able to join:
- People with significant stomach or bowel conditions or symptoms that could affect how the body absorbs medicines or food
- People who have had major surgery on the oesophagus or stomach (such as gastric bypass, sleeve gastrectomy, or partial or full stomach removal), or who currently have an implant in the digestive tract
- People diagnosed with or suspected to have significant stomach-emptying problems (gastroparesis), a hiatal hernia, or severe acid reflux with daily symptoms or symptoms when lying down
- People currently taking other medications that are known to affect how the stomach moves food through the digestive system
- People who are unable to lie on their right side for a stomach ultrasound
- People with unusual eating habits, special dietary requirements, or who are unwilling to eat the meals provided during the study
- People without type 2 diabetes whose HbA1c (a blood sugar level measured over roughly three months) is above 6.5% at screening
- People with type 2 diabetes whose HbA1c is 10.5% or above at screening
- People with type 2 diabetes who are currently taking insulin or medications that stimulate insulin release, which could raise the risk of low blood sugar during fasting periods
- People with type 2 diabetes who have had more than one severe low blood sugar episode in the 180 days before screening, who have low blood sugar without warning signs, or who have been hospitalised for diabetic ketoacidosis within the 180 days before screening
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Phone: (+1) 866-867-7178
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of subcutaneous (s.c.) liraglutide once daily (Yes/No); Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of oral semaglutide once daily (Yes/No); Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of s.c. semaglutide once weekly (Yes/No)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.